Search
Catalyst Pharmaceuticals Inc
CPRXAdd to Watchlist
31.490USD
0.0000.00%
Close 07-14 16:00（ET）
3.85BMarket Cap
17.43P/E TTM
Catalyst Pharmaceuticals Inc (CPRX) Stock Price Target & Forecast
Target Price
33.542USD+6.52%
CPRX Analyst Recommendation Trends
In the current month, CPRX has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CPRX average Analyst price target in the last month is 33.542.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
5
5
5
5
5
5
0
0
3
3
3
3
3
3
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
8
8
8
8
8
8
CPRX Analyst Rating for Peer Comparison
Updated: Sep 22, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
9
21
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Neurocrine Biosciences Inc
NBIX
12
14
4
0
0
30
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Financial Forecasting
Based on analysts' estimates, CPRX EPS is projected to reach 0.485 in FY2026Q2, following reported EPS of 0.521 in FY2026Q1. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q3
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
Forecast
0.33
0.34
0.46
0.48
0.50
Actual
0.43
0.43
0.52
--
--
Surprise
+29.68%
+27.60%
+14.32%
--
--
FAQs
What is Catalyst Pharmaceuticals Inc's expected revenue for the next quarter?
Catalyst Pharmaceuticals Inc's expected revenue is 156.31M.
What is Catalyst Pharmaceuticals Inc's price target?
Analysts forecast that Catalyst Pharmaceuticals Inc's price target is USD 34.00, with the highest forecast at USD 40.00 and the lowest forecast at USD 32.00.
How have Catalyst Pharmaceuticals IncCPRX's recent earnings per share performed?
The market expectation was USD 0.52, while Catalyst Pharmaceuticals IncCPRX's earnings per share (EPS) for the previous quarter was USD 0.43. EPS for the next quarter is expected at USD 0.48.
What is the analyst rating for Catalyst Pharmaceuticals Inc?
Based on the ratings of Catalyst Pharmaceuticals Inc's stock from 0 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.